Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A mutation-independent therapeutic strategem for osteogenesis imperfecta.

Antisense & nucleic acid drug development - 1 Dec 1999

Millington-Ward S, O'Neill B, Kiang A S, Humphries P, Kenna P F, Farrar G J

Abstract excerpt

Given the genetically heterogeneous nature of many dominantly inherited disorders, it will be imperative to design mutation-independent therapeutic strategies to circumvent such heterogeneity. Intragenic polymorphism represents a genomic resource that may be harnessed in the development of allele-specific mutation-independent therapeutics. A hammerhead ribozyme, Rzpol1a1, selectively cleaves a common...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Collagen
Share to Genes, Dominant
Share to Genetic Therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to In Vitro Techniques

Share to Kinetics

Share to Nucleic Acid Conformation

Share to Osteogenesis Imperfecta

Share to RNA, Catalytic

Source

Identifiers

PMID: 10645780
DOI: 10.1089/oli.1.1999.9.537

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A mutation-independent therapeutic strategem for osteogenesis imperfecta.PMID 10645780Read ↗

Allele-specific gene silencing in osteogenesis imperfecta.Semantic proximity Read ↗

RNAi of COL1A1 in mesenchymal progenitor cells.Semantic proximity Read ↗

Strategems in vitro for gene therapies directed to dominant mutations.Semantic proximity Read ↗

A novel DHPLC-based procedure for the analysis of COL1A1 and COL1A2 mutations in osteogenesis imperfecta.Semantic proximity Read ↗

Allele dependent silencing of collagen type I using small interfering RNAs targeting 3'UTR Indels - a novel therapeutic approach in osteogenesis imperfecta.Semantic proximity Read ↗

Hammerhead ribozymes selectively suppress mutant type I collagen mRNA in osteogenesis imperfecta fibroblasts.Semantic proximity Read ↗

Osteogenesis imperfecta type I: molecular heterogeneity for COL1A1 null alleles of type I collagen.Semantic proximity Read ↗

An RT-PCR-SSCP screening strategy for detection of mutations in the gene encoding the alpha 1 chain of type I collagen: application to four patients with osteogenesis imperfecta.Semantic proximity Read ↗

Allele dependent silencing of COL1A2 using small interfering RNAs.Semantic proximity Read ↗

Two new recurrent nucleotide mutations in the COL1A1 gene in four patients with osteogenesis imperfecta: about one-fifth are recurrent.Semantic proximity Read ↗

Cleavage of collagen RNA transcripts by hammerhead ribozymes in vitro is mutation-specific and shows competitive binding effects.Semantic proximity Read ↗

Recurrence of osteogenesis imperfecta due to maternal mosaicism of a novel COL1A1 mutation.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.